Dr. Kewalramani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
41 Mall Rd
# Lahey
Burlington, MA 01805Phone+1 781-744-8400Fax+1 781-744-5245
Summary
- Dr. Tarun Kewalramani is a hematologist in Burlington, MA and is affiliated with Lahey Hospital & Medical Center, Burlington. He received his medical degree from McGaw Medical Center of Northwestern University and has been in practice 22 years.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
- Boston University Medical CenterResidency, Internal Medicine, 1995 - 1998
- Northwestern University The Feinberg School of MedicineClass of 1995
Certifications & Licensure
- MA State Medical License 1997 - 2026
- NY State Medical License 1998 - 2009
- American Board of Internal Medicine Hematology
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
Clinical Trials
- Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma Start of enrollment: 2003 Jan 01
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- 1 citationsContinuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted appro...Oscar B Lahoud, Heather Landau, James Nguyen, Sean Devlin, Nikoletta Lendvai
Leukemia & Lymphoma. 2022-09-01 - 9 citationsAcute Myeloid Leukemia After Radium-223 Therapy: Case Report.Andreas Varkaris, Krishna S Gunturu, Tarun Kewalramani, Christopher Tretter
Clinical Genitourinary Cancer. 2017-08-01 - 46 citationsPhase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga
British Journal of Haematology. 2013-02-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: